Neurophysiological Effects of Daily Centrum Use on Mood and Well-Being: A Cognalyzer EEG Analysis in Adults Between 40-60

The goal of this clinical trial is to learn whether 12 weeks of use of Centrum® Silver Daily Multivitamin can improve mood, and overall well-being in older adults The main questions it aims to answer are: 1. Does daily use of the multivitamin over a 12 week period improve well-being indicators as measured using EEG-based and subjective mood tests? 2. Does perturbation in mood effects due to cognitive load after a battery of cognitive assessments improve after 12 weeks of multivitamin intake.

Inclusion Criteria: * be between the ages of 40 to 60 * Answered affirmatively that they have consumed, or are interested in consuming the investigational product * Willingness to comply with all study requirements, complete questionnaires, records, and assessments associated with the study and to complete the facility visit * Has given voluntary, written, informed consent to participate in the study Exclusion Criteria: * does not currently consume a multivitamin or dietary supplement that includes more than two micronutrients * Women who are pregnant or breastfeeding * Any objections that preclude the application of the EEG headset * Allergy or sensitivity to any products required for the EEG measurement (e.g. conductive gel) * Subjects with forehead skin/scalp health issues. (eg dermatitis, head lice, etc) * History of a clinically significant adverse event associated with the consumption of a multivitamin product or any of its stated ingredients * History of dementia, schizophrenia or other psychotic disorder, inclusive of alcohol or drug abuse within the last 12 months, interest or participation in drug abuse treatment within the past 60 days, or familial history of psychosis * History of any clinically significant brain injury, based on self-report * The participant is currently experiencing a migraine * Significant cardiovascular event in the past 6 months * Major surgery in the past 3 months * Self-reported HIV-, Hepatitis B- and/or C-positive diagnosis * Impairment from any drug or alcohol during their study visit, as assessed by the Principal Investigator or Sub-Investigator * Individuals who are unable to give informed consent * Any other condition that, in the opinion of the Principal Investigator or Sub-Investigator, may adversely affect the participant's ability to complete the study or its measures, or poses significant risk to the participant.